Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by TD Asset Management Inc

TD Asset Management Inc boosted its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 19.2% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 117,780 shares of the biopharmaceutical company’s stock after purchasing an additional 19,002 shares during the quarter. TD Asset Management Inc owned about 0.16% of Ultragenyx Pharmaceutical worth $5,433,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Lazard Asset Management LLC increased its stake in shares of Ultragenyx Pharmaceutical by 36.6% in the 1st quarter. Lazard Asset Management LLC now owns 896 shares of the biopharmaceutical company’s stock worth $64,000 after acquiring an additional 240 shares during the last quarter. Signaturefd LLC increased its stake in shares of Ultragenyx Pharmaceutical by 42.6% in the 2nd quarter. Signaturefd LLC now owns 1,021 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 305 shares during the last quarter. American International Group Inc. grew its holdings in shares of Ultragenyx Pharmaceutical by 36.3% during the 2nd quarter. American International Group Inc. now owns 1,257 shares of the biopharmaceutical company’s stock worth $58,000 after purchasing an additional 335 shares during the period. Arizona State Retirement System grew its holdings in shares of Ultragenyx Pharmaceutical by 2.2% during the 2nd quarter. Arizona State Retirement System now owns 19,722 shares of the biopharmaceutical company’s stock worth $910,000 after purchasing an additional 425 shares during the period. Finally, Chartwell Investment Partners LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 6.1% during the 4th quarter. Chartwell Investment Partners LLC now owns 8,085 shares of the biopharmaceutical company’s stock worth $374,000 after purchasing an additional 462 shares during the period. 96.37% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, EVP Thomas Richard Kassberg sold 39,878 shares of the business’s stock in a transaction on Monday, October 23rd. The stock was sold at an average price of $32.78, for a total value of $1,307,200.84. Following the completion of the transaction, the executive vice president now directly owns 246,860 shares of the company’s stock, valued at $8,092,070.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Ultragenyx Pharmaceutical news, EVP Thomas Richard Kassberg sold 39,878 shares of the business’s stock in a transaction dated Monday, October 23rd. The stock was sold at an average price of $32.78, for a total transaction of $1,307,200.84. Following the completion of the sale, the executive vice president now owns 246,860 shares of the company’s stock, valued at $8,092,070.80. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Emil D. Kakkis sold 47,853 shares of the company’s stock in a transaction dated Thursday, October 19th. The stock was sold at an average price of $33.52, for a total value of $1,604,032.56. Following the completion of the sale, the chief executive officer now directly owns 599,743 shares of the company’s stock, valued at approximately $20,103,385.36. The disclosure for this sale can be found here. Insiders sold a total of 96,864 shares of company stock valued at $3,263,279 over the last three months. 6.80% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

RARE has been the subject of a number of research analyst reports. HC Wainwright restated a “buy” rating and set a $82.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, August 1st. Piper Sandler cut their target price on Ultragenyx Pharmaceutical from $135.00 to $130.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 25th. Cantor Fitzgerald reissued an “overweight” rating and set a $114.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Monday, September 25th. StockNews.com downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Monday. Finally, Wedbush lowered their target price on Ultragenyx Pharmaceutical from $49.00 to $47.00 in a research note on Friday, August 4th. One analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $91.30.

Ultragenyx Pharmaceutical Stock Down 1.6 %

NASDAQ RARE opened at $39.35 on Tuesday. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $31.52 and a fifty-two week high of $54.98. The stock has a market cap of $3.23 billion, a price-to-earnings ratio of -4.39 and a beta of 0.72. The business has a fifty day moving average of $36.06 and a 200-day moving average of $41.51.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.